<SEC-DOCUMENT>0001144204-13-004736.txt : 20130130
<SEC-HEADER>0001144204-13-004736.hdr.sgml : 20130130
<ACCEPTANCE-DATETIME>20130130134640
ACCESSION NUMBER:		0001144204-13-004736
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20130130
FILED AS OF DATE:		20130130
DATE AS OF CHANGE:		20130130

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			XTL BIOPHARMACEUTICALS LTD
		CENTRAL INDEX KEY:			0001023549
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-51310
		FILM NUMBER:		13558001

	BUSINESS ADDRESS:	
		STREET 1:		XTL BIOPHARMACEUTICALS LTD
		STREET 2:		C/O ALSTON & BIRD LLP, 90 PARK AVENUE
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10016
		BUSINESS PHONE:		972 9 955 7080

	MAIL ADDRESS:	
		STREET 1:		85 MEDINAT HAYEHUDIM ST.
		STREET 2:		PITUACH, PO BOX 4033
		CITY:			HERZLIYA
		STATE:			L3
		ZIP:			46140
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>v333360_6k.htm
<DESCRIPTION>FORM 6-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Washington, D.C. 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Form 6-K</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Report of Foreign Private Issuer</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Pursuant to Rule 13a-16 or 15d-16</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>of the Securities Exchange Act of 1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">For the month of January, 2013</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Commission File Number: <B>000-51310</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>XTL Biopharmaceuticals Ltd.</B></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 35%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Translation of registrant&rsquo;s name
into English)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>85 Medinat Hayehudim St., Herzliya </B><BR>
<B>Pituach, PO Box 4033,</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Herzliya 46140, Israel</B></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 35%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Address of principal executive offices)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark whether the registrant files or will
file annual reports under cover Form 20-F or Form 40-F.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" ALIGN="CENTER" STYLE="width: 45%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 20%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">Form 20-F</TD>
    <TD STYLE="width: 16%; padding-right: 5.4pt; padding-left: 5.4pt; text-decoration: none; text-align: center"><FONT STYLE="font-family: Wingdings">&#120;</FONT></TD>
    <TD STYLE="width: 16%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 16%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">Form 40-F</TD>
    <TD STYLE="width: 16%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD>
    </TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark if the registrant is submitting the Form
6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ____</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark if the registrant is submitting the Form
6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ____</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark whether by furnishing the information
contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b)
under the Securities Exchange Act of 1934.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" ALIGN="CENTER" STYLE="width: 45%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 20%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">Yes</TD>
    <TD STYLE="width: 16%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD>
    <TD STYLE="width: 16%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 16%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">No</TD>
    <TD STYLE="width: 16%; padding-right: 5.4pt; padding-left: 5.4pt; text-decoration: none; text-align: center"><FONT STYLE="font-family: Wingdings">&#120;</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If &ldquo;Yes&rdquo; is marked, indicate below the file number
assigned to the registrant in connection with Rule 12g3-2(b): 82-<U> N/A </U>&#9;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt">&nbsp;</DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Incorporation by Reference: This Form
6-K of XTL Biopharmaceuticals Ltd. dated January 30, 2013 is hereby incorporated by reference into the registration statements
on Form F-3 (File No. 333-141529, File No. 333-147024 and File No. 333-153055) filed by XTL Biopharmaceuticals Ltd. with the Securities
and Exchange Commission on March 23, 2007, October 30, 2007 and August 15, 2008, respectively, and the registration statements
on Form S-8 (File No. 333-148085, File No. 333-148754 and File No. 333-154795) filed by XTL Biopharmaceuticals Ltd. with the Securities
and Exchange Commission on December 14, 2007, January 18, 2008, and October 28, 2008, respectively.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>XTL Biopharmaceuticals &ndash; Immediate
Report</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Below&nbsp;is
a summary English translation (from Hebrew) of an immediate report by XTL Biopharmaceuticals Ltd. as published on the Tel-Aviv
Stock Exchange Ltd.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: left; width: 50%">&nbsp;</TD><TD STYLE="text-align: right; width: 50%"></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><IMG SRC="image_001.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: black">Herzliya,
Israel &ndash; January 30, 2013 &ndash; </FONT>XTL Biopharmaceuticals Ltd. (the &ldquo;<B>Company</B>&rdquo;) announces that
on January 29, 2013, the Company filed, with the District Court of Tel Aviv-Jaffa (the<B> &ldquo;Court&rdquo;</B>), an urgent
request for settlement between the Company and its shareholders and between the Company and its Series 2 warrantholders (the
&ldquo;<B>Warrantholders</B>&rdquo;) pursuant to Section 350 of the Israeli Companies Law-1999 (the<B>
&ldquo;Settlement&rdquo;</B>). The Court was asked to permit the Company to convene an Extraordinary General Meeting of
Shareholders of the Company and Warrantholders in order to extend the exercise period of the warrants (Series 2) (the <B>&ldquo;Warrants&rdquo;</B>)
to December 31, 2013 (the <B>&ldquo;Extended Exercise Period&rdquo;</B>). The Extended Exercise Period would enable each
Warrantholder a better opportunity to exercise the Warrants. Any resulting proceeds will be deposited into the Company's bank
account. &nbsp;However, there is no certainty that the Extended Exercise Period will ensure that the Warrants or any part of
them will be exercised.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Warrants will expire on February 27,
2013. According to the instructions and guidelines of the Tel Aviv Stock Exchange (<B>&ldquo;TASE&rdquo;</B>), the Company is required
to provide to TASE, until February 20, 2013, a judicial order directing the extension of the Warrants. Because it is not viable
to complete the necessary procedures by that date, the Company filed with the Court, in addition to the above Settlement request,
a request for a temporary order whereby the expiration of the Warrants would be extended until April 30, 2013 in order to provide
sufficient time to complete the necessary procedures.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On January 30, 2013, the Court accepted
the Company's request to convene the meetings mentioned above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company has issued, among others, shares
and 18,457,500 Warrants pursuant to its public prospectus dated March 7, 2011. The exercise price for each Warrant is 1 NIS, linked
to the US dollar. The exercise period runs until February 27, 2013.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Prior to the submission of the aforesaid
requests, of the 18,457,500 Warrants outstanding, 6,154,095 Warrants were exercised.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; margin-left: 2.5in">Respectfully,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0in; text-align: center; background-color: white; margin-left: 2.5in">XTL
Biopharmaceuticals Ltd.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: left; width: 50%">&nbsp;</TD><TD STYLE="text-align: right; width: 50%"></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>About XTL Biopharmaceuticals Ltd. (&ldquo;XTL&rdquo;)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">XTL
Biopharmaceuticals Ltd., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of pharmaceutical
products for the treatment of clinical unmet needs. XTL is focused on late stage clinical development of drugs for the treatment
of multiple myeloma, schizophrenia, and hepatitis C. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">XTL&rsquo;s
lead drug candidate, rHuEPO, for the treatment of multiple myeloma blood cancer, was granted an orphan drug designation from the
FDA. rHuEPO has been approved for marketing by the FDA and has for many years been sold for billions of dollars across the world
for the treatment of severe anemia. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">XTL
holds the controlling stake in Proteologics Ltd. (TASE: PRTL), a drug discovery company, and InterCure Ltd. (TASE: INCR), a company
which has disrupted the $42 billion hypertension industry with the world's first FDA-cleared, OTC blood pressure treatment device,
RESPeRATE&reg; (<U>www.resperate.com</U>).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">XTL
is a public company traded on the Tel Aviv Stock Exchange (TASE: XTL) and its ADRs are quoted in the US on the Pink Sheets (OTC:
XTLBY). XTL shares are included in the following indices: Tel-Aviv MidCap-50, Tel-Aviv Biomed, Tel-Aviv MidCap, and Tel-Aviv Bluetech-50.
</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Contact:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Investor Relations, XTL Biopharmaceuticals
Ltd.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Tel: +972 9 955 7080, Email: i<U>r@xtlbio.com</U>,
<U>www.xtlbio.com</U></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: left; width: 50%">&nbsp;</TD><TD STYLE="text-align: right; width: 50%"></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Cautionary Statement</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Some of the statements included in this
Form 6-K may be forward-looking statements that involve a number of risks and uncertainties. For those statements, we claim the
protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: left; width: 50%">&nbsp;</TD><TD STYLE="text-align: right; width: 50%"></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SIGNATURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the requirements
of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-align: justify; text-indent: 0">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding: 0; font-weight: bold; text-align: justify; text-indent: 0">XTL BIOPHARMACEUTICALS LTD.</TD>
    <TD STYLE="padding: 0; font-weight: bold; text-align: justify; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-align: justify; text-indent: 0; width: 50%">&nbsp;</TD>
    <TD STYLE="padding: 0; text-align: justify; text-indent: 0; width: 5%">&nbsp;</TD>
    <TD STYLE="padding: 0; text-align: justify; text-indent: 0; width: 35%">&nbsp;</TD>
    <TD STYLE="padding: 0; text-align: justify; text-indent: 0; width: 10%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-align: justify; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-align: justify; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-align: justify; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-align: justify; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-align: justify; text-indent: 0">Date: January 30, 2013</TD>
    <TD STYLE="padding: 0; text-align: justify; text-indent: 0">By:</TD>
    <TD STYLE="padding: 0; text-align: justify; text-indent: 0; border-bottom: Black 1pt solid">/s/ David Grossman</TD>
    <TD STYLE="padding: 0; text-align: justify; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-align: justify; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-align: justify; text-indent: 0">Name:</TD>
    <TD STYLE="padding: 0; text-align: justify; text-indent: 0">David Grossman</TD>
    <TD STYLE="padding: 0; text-align: justify; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-align: justify; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-align: justify; text-indent: 0">Title:</TD>
    <TD STYLE="padding: 0; text-align: justify; text-indent: 0">Chief Executive Officer</TD>
    <TD STYLE="padding: 0; text-align: justify; text-indent: 0">&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 6; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D
M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"
M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#_\``$0@`+`"0`P$1``(1`0,1`?_$`:(````&`@,!````````
M``````<(!@4$"0,*`@$`"P$```8#`0$!````````````!@4$`P<""`$)``H+
M$``"`0,$`0,#`@,#`P(&"74!`@,$$042!B$'$R(`"#$403(C%0E10A9A)#,7
M4G&!&&*1)4.AL?`F-'(*&<'1-2?A4S:"\9*B1%1S148W1V,H5597&K+"TN+R
M9(-TDX1EH[/#T^,I.&;S=2HY.DA)2EA96F=H:6IV=WAY>H6&AXB)BI25EI>8
MF9JDI::GJ*FJM+6VM[BYNL3%QL?(R<K4U=;7V-G:Y.7FY^CIZO3U]O?X^?H1
M``(!`P($!`,%!`0$!@8%;0$"`Q$$(1(%,08`(A-!40<R811Q"$*!(Y$54J%B
M%C,)L23!T4-R\!?A@C0EDE,88T3QHK(F-1E4-D5D)PIS@Y-&=,+2XO)59756
M-X2%H[/#T^/S*1J4I+3$U.3TE:6UQ=7E]2A'5V8X=H:6IK;&UN;V9W>'EZ>W
MQ]?G]TA8:'B(F*BXR-CH^#E)66EYB9FIN<G9Z?DJ.DI::GJ*FJJZRMKJ^O_:
M``P#`0`"$0,1`#\`WUDEI(2E/(Z)++K2*&,^,RLCO.RQ(Y9F.D$M]>+GVR5&
MY5D8D@8)X9'V_+IJ:6':Y0%KWBHQJXX\AT3C^8!\N,?\)?BCVG\D,AAI]PS;
M#Q8EPF$CIJF2&?,U4T5%0QY&2%&,-&):C4[DHMA:X)!]B+E/E[][[[!M<E?#
M=P#I8`Z3Z$U%?RZ).8MWCL=M:^C^-0.*FE3ZC'6K1_+I_P"%(?R0[F^7&P.G
M?DILG84_7_<^ZZ+;F&K-@8G*MFMGYS.&6?%0"!,UFY,C0T\4<J.4B'Z5.H?G
M(#W"]B+'ESEW^LEI]06MHM9U31D>7%0@)_;U&VP^Y-UNFXKMKB+PV)&(W!H"
M`2"S?,>76ZPABM,6F%*S4\3565BEC@!E<.45XIA(8](/%_K?WC!(L[,&.G2#
MZ]3%%=QS((`6)``X'%?GU.-0)1$U//9%(D<R1MJFB`T:Q]!I+`^H"WNMS%<U
M"]E1\Q_GZ?0VUO5I==3Z>O[.I81R3(`S%Q?GA`/[(46!_3_B?=D\1XS%<Z0G
MR_XOIE8[9YC<=]2/0^GV==$.#S'_`+W[1#;+?Q_%J:5]1T\9;<#2=7^\G_-U
MRTNWUBX^EQ>_LU/AZ=-<?ETRT5HXQK_8?\W49W2&58BY228#PPL"X<H2\A1%
M`=F$8N>>`/:"6R#6S+'DU]1\NM)<6\$@MUU:F!.0?]7EUP14ATHTJ"_D"B(:
M''D=G-D8NQ.IN?;MT113FH0#]E!T];G5`ZCS:O6&J1X8_.'G(@)9W\D:%%_+
M$M&0;?T]V>W^IDB]*>M.D"70L;*XF;@ORK_+K%1UU/6*L]%,E;"&8R3QSQ.J
ML;>DA/J??KRT>XE6-Z:%]"*YZIM=U$UG-=Q5-<FH(X5X#IPX<`WN"`')_5P3
M^!Q]/;5W.^W1)'%3B>.?\W2M&@W*U_5)JM2:8_PUZR)&(]3@%E9;`$_J_%CP
M#R?:M)99;<,:>-2N.%?+I1&H6V2"#**?/C3/V=0EK8:DB."6%VC$FJG1A+*/
M!*(9!96)M%)Z3QP?;$<4D@+7U`_]$C_9ZM'JAO#'(*+X=?VT(S]G4XNS(!QS
MR!I*D#\`@D\@>W(O`5M2$\//_BNO021%Z*36G6)#(DUI@H8CC3<\$D#^OMSP
MH&;QHBQ8"F?^*Z0646XLACNE06]2:@YK^W_)U+'CN`"U_P#??X>VII)4%12G
M2KQHY?T//_-_Q75)G\[GX<]J?)[XJYW=/0^]]\[([BZ>I:[>FW:79^X:[")N
MJBH8V?)X?("DD1YY%QOW$D2QM&S.%%R."-/;#>MNV_=OI[M4:&1Z59-5"13S
M!^P8X]`SFK;+_<+4SQU!C'DP&*US4_;UHY_!3YC;AQ'>%1T/\PMX;_["^.W?
M%'4]-=N[;W?N#(Y*;:^X)<C2(=P8<Y*<R4&:P.>PRP$RZX!"TFI"UF&6?,/+
M%O9;$W,FQQA[J*(.`0B+Q%>`5N!QGJ&;+=+NZO#M-]B+5IXL33R.21Z>75Y?
M<7\L[X>_R5=AU?SSJ>W<YW;OO;8JJ'XF;4W-5X&HQ+[PW$C56T<U]KMC%83(
M9NAPN,H65ZD2RQ*9T);UB\;\O<\[USSNT'*=Q"@LIW\.4AF+)'YD:G*EABG:
M1QQT)MQV>PV*`WL+'QZ!E!&&(KFH`(!S7(SU39_+>V'\T_YD'RYV[UW-\@NZ
MX-LTFYXMV=U9^GWID:#^![/DJA4+2T&EDQ$>0^VH:L1QO$]R%&D^Q=S]MO+G
M*6WOK`,JJ0`T:9/D`0E*D])N7+Z^W.Z$D9P2*49A]N"?+JX;^=]\4_YAN:^6
M&RJ3XB8KO2HZBV]TEMG;U0^R]Z5D%)D,Q1U^;AJ:Z?7D6E^\J4>-Y2UB6)L`
MMA[`7M_S;RQ#"J;V8?&-=1:$-3)H*Z*8%!TJYSAWN1Q':@TKBCD>6?Q#JAON
M?JG^:G\=MJ3=C=XU?R.Z[V5-D<=B(L_D^Q<P].*TT0CIZ)8XLM,4,L4!D8E?
MU`\CZ>YCV'<O;_>]UEA@>%J1:J+`O`%17,?SZ`VXKS)M6VQR2:J,Y%3(WH3Y
M/7H.NCIOY@OR6SF5VUT-V)W[V;G<#1RY+,8[`[^SOEI*!98HXY6,^015/[RA
MB>+GCV;;XW(&U0>+<-$BUXF!!]@_L_/HFLI^8+^<+$7)(7_1&XTS^/@#CH;]
M^?&K^<9UEL_<?8&^*'Y*[=V;M*AK,EN#-5G8V2>&BH:.%IY9V\669M*1QL3P
M?I[!NT[][?[A>K;1/$SFIH(!7'VQ]"Z>UYFMK;Q&#!12I,I('VT?HRG\B'O/
MNW>/\T;X^8+=O<O9>[<!D*'?QK,%N'=^9R>->2FV3N*2,5%+4U3PR2Q3Q!AP
M1P/:?WFV#98^4GW#:%73'HU$(B<6`\E4GCT]R%NFX3[ZEO>'N:M.YCP!KQ)I
MCKZ4"P+Y$=AK>/R$.UKC4S\<``@`V^GT]X5W(UMCTZR3MB8K4K7B<]`K\C_/
M2]%=IU5+5U-)5#:=?-!5T\S13TLR",H\#I;0R_2_L;\@PB]YJVZT8`JTP4B@
MS@\:U'4=>YEX-HY'W/<&)5%MZUSCN4?ASU3W_(LW=NC=W4_:]7O'<V6W57T^
MY*0T;YG(U-;6Q12OE?)'&#((D@;0ND:0>/<L?>'V&WVC;-N&U+^M*)M0HBY7
MPZ94*?,^?6._W4>:][W2_P"84WP`6*M;>&0SR$@^/7M9GT\!6@%>KY#/(5")
M&`[`^0LKA8Q;^G#-Q_2_O'&SCDCV]9+L#Q0A-"0<^7KUF(MWMCO+"CN"P(^!
MAQ'^EZXU*S&DJ($0R+-3RQL_D"%1)&RL4NRNI`-P?Q[=L+Z.:99&H-!!P/0]
M%5]9W8V^:VM`6,\;(*M0]P(J#44(K@^75/'Q!^)7REZK^87;O;796]#D^G]R
MR;VDV9MS^/U&1_A\>3W92UV'!HS6U#1_[BT8M=>&-N/I[G7FWG/E?>N48H+#
MPCN6E%;3#H(TK1B6*"N1Y'-<=0#R'R%SKROSRR[C]0]D(B`9+@2`U*D8#D5I
M^SJY$5,88J&!O:U_U>H\*([>0*+<$CW`-K?6=T=,#5:OH1_A'63B6\_CU8`#
M3Y$=<&)A.EHY6+MZ6^H`'U.JWI`O]/J?Q[M$MZ]SXC*HB''(_P`%>DMNT=DA
M\1GH6\P3_@'7DJ6-O(%$FL)8*Z"WY/KY/I]JYBL,>IZ4/Y]+I;-'_7@U4(KY
M=8YX!.":A$DCE9HS!(#)`Z2KX9XYHO4DD<M.2"K`KS]/:258[$>/"Q$@((\L
M_EG!ZNYC:/P10ZA0U`_R]?/$_P"%$'\M>7XG_(.#Y,]28,TO2G=^4JJ_*PT-
M).:+8?:%49JNOD*TR2O2QYZKIJRN5U'B1I`OI-E]YA^SW/-GS)LDG+^YR4N>
MU1J+.6%.(U5'V@TSPQU`/._+_P"Z+L[G;5[LT``^WA0_/JHSO+Y<_)#YB;8^
M,'1F^,C5;R3H;;9ZNZPP&-1ZJLW3D)(L!C16Y-1!&:O)4RX!/%).Q>TCZ#8M
M[DFVY5Y8Y+6[YBN9A%(1J7])`*CC0HI8=1U]7NV^/])"'<`X.ML*>!RWG_+K
MZ$'\FG^7#A/@!\7\519[$T]?WIV534^Y>TMPR1P-E%,T.JAVN*N1]`2D:2<*
M(B!>8W/T]X<>YW-\_->[R+:R,UD&H"&:C?,`G`],`C/61').Q0[3M:R7:!+@
MK730'3\JY/VY/V]7(Z%!BTH3Y@ZF5E0FGTQ%D4AKW`<6L+B_N-H;2>%?[20M
MYU;A_/H6K;PSN7"J1ZT'^7K7/_X5#!A_+;A59735VWM(&2,(M_\`(LG<,!IL
M'(MQ_7^GN>O8:41\S72M1I&LB`#G/B1G_`#U%_NR6@V:V6-%*_59\J#PWSCJ
ME;_A*,=?RR^0J0I)$S=50'3$(61#%6X1)92LQMJ\I'T')/L9^^#3Q;9'#*@2
MLZG'^E;&/MZ#'MBXO;KQ(XT-$KP&/+S_`.+ZVQ_YMS2#^6U\QBKM3S#H??\`
M-#)%I!2>/;>2(TGZWU6Y]PA[:7%R>:())D"TJ.->/4J\Y2P6FSR*J(3QI3^?
M#CUH/_\`"?9/%_-6^."?JT4G8W[I-S.3LC<SM(U^;DL1_L/>7?O$$;VRN[F,
M`1?H9&.,J#[>H,]NI5N^;XRU%T>)@?Z1NOJ`:@-?_(7_`$-[P+M768,5-0'I
MUDQ.X1:#&.@/^2=VZ"[4_P`-H9$C_6TI[&_MC,&Y_P!OC3+"Z&/]ZZC'WJMS
M=>U6[QI74;/RX_$AZU)?@!W7\B:38FX_C5\5]M^3M7?.5@SE7ON=\?#1;:P+
MM5^>6=JUP'^R6HN`D;R&QL#[Z">\?(?*EI8[9O\`S;?26MK"KE%,2.CEM!-0
M%8^0ICSZYJ^S?.?/^Z3[EL/*&VI-(60.\<S1.*:].2Z`\3ZTZ.WO?XP_S<.E
M</D.SL5\@9NPJC"T=3GLU@XLCYJ2*DQ4+9&J7[7*44,3(T4;+IA4L;?2UO<"
M[)NOLIS#=+L=Q=&TFD98T+6L9ULYT@#3&U#4CXJ#/4X\Q\L^^FU;0=YMK2\D
M>)&DF'UE`B(-3$GQP30`X%3CAU87_+=^=TWR[Z_S^W=W4D^"[@Z_Q]=!N-&:
M%4J1!4&B_B$-*C&$L*B=1I,8OIN1;W&'O5[7/[=[C:76U^)/R[>W"HLSK$E9
M"*E`J$&@0$Y6GY]3#[">]L?/'+E]L5\T*\U[?9R2R1`S.RJ"55B\@(J6(':Y
M-?EGHL/P4^3???9WST^0/6&^.Q:_-;)VE+OA=OX:7'8>FBIQMK=E%@:>.]'0
M02*&IG9KZN?SS['7N)[?0;%[4;;S(D(6SN)8XEE"1#6[H[L#I&O!5@*BA`X]
M1K[+^XN_[][MWUK.SS&*VED9&FE90%D1>#M3&H<,CIR^=?\`,3[4I.UD^*?Q
M#QPRO;U14TF-R&Y_MJ&HHJ2LK2T=3C(VKHI0M1B)D*R2:-%R+.1S[1>W/L=L
M]KRM'S_S_<3;9RZ\RB&41PRI*7J4!5?$<!@/-13SZ/\`W)^\#S)N?/!]MO;V
MS@O=Y,0U*LLT,BG`<!B8XSI-/Q9Z"QOA5_-LCP2[VHOE<U3O!X5R,NS):L-&
M*LKYEH8S+C#BUBU^EAK`M[%<'N/[.IN)Y?W&&WCV2IK>+:QE_13I,==)I4]M
M:<!7H`S^WGWA;>T_?D4&XR[_`.(/\2:__3T,>YM7U&G&:#5Y<.AH_EY_S%.R
M][]GYKXO?*2CAQ7<6"J\CAZ#+&"GIZ;)5N*QPKI$(ABAA+-2QLX8+9SP"3Q[
M"?N7[)R[7RZW/?+'C7G*)=6:8B%$5)&"H0E5?+,`.S%<TZDKVB]\[QN9X?;W
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M_,G8WSN^,/7/?NR)(F.=QM-'N;`2-$E9M[==!'"]913I$S^A6F0W-N/H/?/7
MFKE[<N7=S:VNHY$",=)8`:P//!(ZRYV._M-QM0492U,@9`KQX]'C5?(JGT_U
MXM:_TL/]8^R6&?Q%-<-Z=&PI%51@?LZUP_\`A44-/\MN.WX[>VA]/\:;*'W.
MGL%X0YOG,E*?2'C_`,U(^HL]U@'V.)O2?_GQNJ5?^$GA)^7/R%_PZHGYO^/X
MQM[_`(GV/OO$7-N;6)5TXE4D_+2?ET%?9OPU,BU&KP_^?AUMC_S</^W;?S%Y
MY'1'8/\`[S>1]P)[:W4,O,T$@(*"M?V8\NI.YV$;;6P-*]:$'_"?GG^:M\;_
M`/J"[&_]XG<_^]^\Q?>);23VMO(O$"2$0$*!Z2H?LZ@/VY+P\VHR+J4EZ_+M
M(Z^GZ`/7^20QM_L??/FVBCM]060Y:OIUE$VJ2,G3Z]`=\D[CH+M(H"Q.S\AQ
M>W]B,^QW[6PQ0>X&WSZZJ;H$_L/4<>\4DD7MGNH1=1^DI3_;*.J&?Y!.S<1+
MBN\M[U-#'4YRAJ-JXG%U9C1Y:>FK3N,5:1NW*`^!+V_I[RN^]=N^\G;MALIA
M*+&3Z@BKDA@G@TQ7Y]88?<;V7;XN8>9;^[=6T-:@*R@@:C<5(XT.!7UZV-:V
MF2>CK*.<"H@KD>"M@DL\7VM5'X)XY$:ZR(T9-U(L1[PIEOGL;NVFMXQXIE6C
M#!!!!#`@5J/+KHIN)VO<]MO-O;PQ']+(K4`-0R,,BGGUJQ?`P_W0_FJ]X;9P
M$TE'ALD^\:6HIJ8F.CT)C9:^$>)&$8M4QK;C@^\]/>2\&]^S.R7EY:QK<++$
MX8T9M0706!(J"14D\?+KF%[.6=GL?NUS+:6-U0M921@`:*ZG#`&AH0#P'#SZ
M6_\`+H>7'_S(OF=623B=Z?`]T-'I_P!U54._<?(6`/"LQC/^W]E7N:TD_L=R
M_8.S-;C<K=@":@:DE_"<8#=*/8U[7:/>;?8WN/\`&UV>Y8J:@Y>)N(KTW?RC
M<72=C_-OY&=D;H5,IGL1696LPAK0)FB_O%D*V>::`R!Q&<>:)`"!==7%O:[[
MPMS+L_M);<OV`)VY;V`KI)1!H#CX%P*UX=%7W8K*UYI^\-+OEW<L]TVV7+T/
M>0VJ*A#,:U%<'K:&IHY8X$-1(C2QJAEE6P1M!+:B```"/]Z]X%744-Q/H5R'
M(&/.F>NHMM&X7QP3++\-#_AK^?6KW_,UP&-ZL_F0=";WVD3A<WNV#8>1KSCE
M%(LU9-V!68>KDG6!D5GK,53"-B0=2GGWG+[3[A?\T>PF[;-N+.UE;7?@@LQ<
M45(I5[6P*,V`.!R,]<ZO?*&RY7^\9L^X;8$2^DVR24HBB,AF:Y0]RYKIR3Q(
M-.'5S7\R3YO[/^`_Q@W[W7N*:E?<ZXVLPW6N)GDB$^;WK71)38N*&F=@]118
MR:K2JJ0MR8(GX'U]X:<L;+^^MYBMY:A"V32M!Q]1@\./GUG_`,T;U^Y]N9Q0
M.5[>[2:\,8/7S<OCAU5WM_--^>-%B\S5Y/<.].X-Z2;V[.S\R5,JX39:U_DK
M)J>J=IWAQ^,CGAQ]$K%5AI72,&P`]YU[]O.R<I\F"*V^G1EME``(0U"CA0')
M/6/&UV6Y;YN_B3^,R&0FIJPR<5^P&G6WG_.^_E';'WC\"^OLU\>-JBFW[\--
MH)B]MXO$8FG@S>\>LL=08VBW%03242_<Y#(5#X6@D1B&##63;WCA[<>XMZ><
M8TW6=VV^>XJ1),2B#/;D4(_9PX=2OS#R9:GEZ:>T11<10U&F,:F8<#\6#QX=
M:[W\A_\`F5Y/X3?)S%[`WIFZN7X]]_Y*AV]N45DS0T>P]PS3U%#@=WI!-*U+
MCZ:2MR3'(GT%X:5+MP+2M[L\O;3S)MTFY;<L1NT4NH1`S,!G34$8;AP/V=`;
MD;=]TVR[%K>F0J30ZG-/]FG7TJL54TE7C*"LQTR5%#6TE/6T<\+!HIZ:LB6J
MAGC925*3QS!@0;6/O#211#*:@+4TIPI0\.L@RTDD2O0Y%>M=#_A47)(G\MM&
M$32QCM_:/F(37XT^TR@5_J-'[I47_P`?<U^QDD4?-TGBL%5K4C/KK3_-U'/N
M7$]QRZ@3XA/4_P"\M_GZI<_X2A(R_+3Y#!=$<R]3P-*C6+JDU=A'!4?@LP!/
M]?8_^\';VSVD4B.IU2**`?T3\^@/[1)<1S-VFOAO_P`>Q_L=;6W\W5RG\MGY
MD.)72.+HGL)9':+R.0NW,CJ`NZW;_'W`WMQ;P6W,,",RA*DDG'IU)_.$<\NV
MN`&!H/\`+U\X#^6[\LL%\'_F#UI\G]Q[3R6[=N[+I=VPG"4"K#+.F<VWE\''
M)$VB8(\=17:E]/!%_>;G.O*!YRY(+6MV\<1,8(1-8-&7![E^WK';E_=I.7M]
MUL@DD!."V@FH/#!ZVN3_`,*T>CRCZ/B]V4ZBH6$.N;".ZO$)]:VPI(`OR+_3
MWCS/]WN[!!6YGR*_[C?]=>I1C]V-,11H(M53_HY]?/LP>DQO3_A4?TUVUMC,
M]:XOXY;XQT^\Z*;;L.1K<WJI:.>K&GR3I_!T#:-!_M#V)>5O8BYVOF"QN3=R
M@B0'_<>GD?/Q3T"O<KW);<^1=QMTMEHUJ?\`12?Q+_1Z7?\`)Z^5&R?CIOC=
M?6'9N73:VW>SVQ4>W\]DJA5Q:9W'-D4:GGJYC%%%,6R::OJ?<N_>8Y'WKF'E
M;:OW.EQ=7M@)$_334Q$GAU<]U5IHK3-?RZQ"^Y[[BV/+7.6[Q[^T5OMUYX53
M++I4%#)3!4@_%\J9ZV&^[_EQT5TEUIN/L#-=B[8JZ:@QU;64%%2Y:DJ*BOJX
M*1IJ2CIH5E5I!+,%%@?JWO##8?:[FW<MUAMKRUO5MQ*@9VB)$09@"YJ>"\3D
M<.L[^;O?KVYV?9;N7;[W:IMS-M(JQ+.H>1M+4&$-22:#!ZI3_E!=8;A[5[O[
MK^6^<QU?0[>SL^X8MJSY"&3575F0K_,LD;RA188R8HI%R$4#Z>\FO?+FFSM^
M4-JY.M`GCP3*&"MDHL9764`P"V:5XGB>L4/N\<E7',G-._\`/%Q)(EN]D\B_
MIZU+:P=`D+#@!QT\/+II_EN4A?\`F9?+VBDBIXXLLG;-%4&9A,2,EO\`Q\L\
MBQ$)9HFNHY^A]F/NE#'%[`;)=0S:ITOH30<2%CEIFOV?9T5_=^L[3=/O$;_/
MN$B1VTFS3HH8!EU>+;I05(J2*FGI7H.]B;H?^6;_`#*=XT?8-+44'4G9^4S\
M>%SM1$T6-CP.;R,<^&D21[4\8BII/H&LOX]K=[%M[E^P,,BS*^_K=!]`_5EK
M$""A-5(KJSZ4X'HJV6#_`%BOO)RW8`_</[O\,$_XO%2XTMJ%-8HNC\Z@U%.M
MCFI^1?1L6SJC=K]C[2@VY%@UK9'7-4>MJ1HYI6B8:P"_CO8<\GWAROM?SL^X
M"-++<#<DD!?"-:#S&>'6?D'O/[?6VU_6?O';3<J-7AF9:D^GP_Y.M<:ES.9_
MF7_S']I[BV91S5O4/65;2/4;@=7FIZ:GVC6U.9I:6&8*T/@JLC&EEU`:I#_7
MWF?,FW>TWW>K[:I)8AOUU+%(5:D,S.[Q(V!J+%54U/F!3'6".V+NGO=]XFTY
ME>VG&S01W$)8$SPHHCF9:DA``S,-(I0$@YZ&'^>Q_P`-I?WXZ9_X<2_V9K[?
M^!-_HZ_T9?W6_N-J_BN=^X_BW\:_=_O)?[CR:?3]CX[>J_O#SDOZ[Z[_`'6^
M#]57\=?\G\OGUG9[C:/"C\;7X=/*E*U-*_G_`"ZQ?R*/^&EO[]]R_P##?G^E
M#^_G\)']Z?\`3+_=K^-_W7^[Q'W7]S_X#S_`_P"+?;:_)ZM=OQ[%'N5_7;]T
MQ?OK1]/J[?#KQS2M?EU?DW]Q_2CPM/U5!6O&M,_SZV2<C]C]A7_Q+Q?PG^&/
M_%/N='C^V^W/_'3]OQ>'7KU<7M[A_:OJ/$'AU^JJ*>M?RZD0^']*_P!13Z?1
MFO"GGUH#]Y_]`U'^DGM_^\7^S6>7^_\`E/X[_HX_T?\`\._O#KB_C']V?N_7
M_=JWC\&K]S5Y+_CWDIMO^N#^X!J^FU:6U>/KU:*"GP_BXU_+J)+W]Q_OQ?IZ
M>%J73II2E?GY=;O_`,-/[G?[+#TM_H[_`-(?]PO[FTW]T?\`2O\`8_Z0?X#]
MY6_P[^\W\-_R'[KP6\7C]/VWC_-_>.V\T^O:FC^TSH^&OG2N>/\`/J98O#^E
M6G#3T1_^=7_LF'^RAQ?[/7_I(_T)_P!_\)_S+'^#_P`<_O#]K7?P_P"Z_C7^
M2_P[QZ[V]?DT6_/L6\B_OO\`?0_<%/K=&:U^&H]/G2ORZ`_-GA?NIOJ?[+5C
M[?\`BN'5=/\`(P_X:/\`].?:/_#?7^FG_21_<EO[X_Z3_P"[/VO]W_N<=XOM
MOX'^[K\GBMJX]B[W0_K?]`/ZP>#\8IX=?BH:<?ET'O;;Z;Q&\.NG0VFOIJ%:
M?GQZO#^>_P#H?_V3[OC_`&8+^\/^AK_1IN__`$B_W<^S_C/\`_@]1_$/L_OO
M\E^X^VUZ-?IU?7W#_*G[V_>L?A^)XE1Z5I7/4B<Q_3?2OXFG10_9\NM(&D_Z
M!E--9J_V=+[#R?N_:_Z-_M_-<7^UU\^+R_2_YO[RB/\`KX_N`_NOQ?W5J']G
M6E:BG'SX5ZAG;/ZD?6M^]/!^HJ:>)QX9X>77A_T#,^&'R?[.WJ^YDT:O]&OD
MMID\=[<:?#;_`&'N\O\`K[T37X]-`IQ]!Q^?28_U%[]'@<3PKPU8I\JTZ=L)
M_P!`S_\`>#!_P;_9Q?[P?Q*/^%^?_1Y_#?O+MH_B&C]W3:]]/O8_U]_WE:U^
MI_HZ?L\^DO,W]1OZFW]?`\7Z;RKJI5:T_+J]:A_X:/\`]E$W7K_C_P#</^^E
M9XOX_P#PC_2/_>S4_P!S_=CP?Y+]EY-/CU^KZ7]G4?\`P0W[W;]Y?7_2]VKQ
M?['3BG#->.G\^H#LO^!S_<2_N+]T?O\`^GCUZ-7C:J'XZX]>'5>'7'_#5W^D
MA?[\_P"S#?W8_C-!_#O[]_P'^[OD^XA^SMX^?!YK>3_:/I[%]W_6K]SR?N'Z
M;][^'^I356N>'S_A^?40VW]0?ZT#^L'T_P"[_$_'PTXK^5.MN?H+_1!_HMV_
M_H0_@'^CS^"+_"OX9I\NO7)J\WA_:U>"_P#C>WX]X;<S?UQ_K%)_6GZCZJHI
MXGI4</EZ==%/;+_6U_JO)_4/Z']V^"WC^!6E*=VO\N/59WQ"_P!D=_V=;O7_
M`$%?WP_V8.^\O](']Y?X;_=[7_>FB_C_`/#OLO\`*_\`BZZ?'K_LWOS[DOF[
M_7'_`-:VT_>GB_U9^H'@U^+722E?+3353SI3J$>1?]:W_76N/ZK_`$?[R\-]
M?A5^#4NJM?+535_2Z'_^8-_LFW^BF?\`V;;^&?P34O\`!/M?MO[U:=!T_P`/
M^Z]&G3IT>R#VM_UP]#_N/Q?H?&'B:J^%JJ::J9]:TZ%?OM_K*^(/WY^[?ZQ>
M`NFO]MIIV?EZ=:S5!_PV/_>I_P"*?[,__<3[I;^7^`?W?_A'D_=\GY\?@O;_
M``]Y>;E_6#0O[O\`H/ZQ^":>#K^*GE7Y\>L$(M']=4\;Q/ZK?BK3PZ5_S=;2
M/\OW_92?]%U-_LJ/\(_@6AOOO#]O_']/BCT_Q'P>CRWTWMQ?WB)[K_ZX7[PB
I_KO]1^[Z=FO^RK4_#UGO[$_ZV_[CN/ZH?2_OSQCKT?VM*+7^7Y=?_]D_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
